NexMed Receives Additional Patent Coverage for Israel
2010年8月23日 - 10:00PM
ビジネスワイヤ(英語)
NexMed, Inc. (Nasdaq: NEXM), backed by a revenue generating CRO
business and seeking to leverage its proprietary, multi-route
NexACT® drug delivery technology and internal pipeline through
out-licensing arrangements and partnerships, today announced that
the Israel Patent Office has issued an allowance notice for
NexMed’s patent application entitled, “Topical Compositions for
Prostaglandin E1 Delivery.” The patent, when issued, will provide
coverage to May 13, 2019, and expand the protection of NexMed’s
Prostaglandin E1 (alprostadil)-based products in Israel to seven
granted patents. NexMed has several alprostadil-based treatments
under development, including Vitaros®, for the treatment of
erectile dysfunction; Femprox®, for female sexual arousal disorder,
and RayVa™, for Raynaud’s syndrome.
Commenting on today’s news, Dr. Bassam Damaj, President and
Chief Executive Officer of NexMed, stated, “This addition to our
patent portfolio strengthens our intellectual property position and
bolsters our ongoing partnering discussions for the licensing of
our products in Israel and the Middle East.”
About NexMed,
Inc.
Backed by a solid, revenue generating CRO business, NexMed has
leveraged the flexibility of its proven NexACT® drug delivery
technology to enable multi-route administration of new and improved
compounds across numerous therapeutic classes. Future growth will
be driven primarily through out-licensing of this technology for
the development and commercialization of such compounds to
pharmaceutical and biotechnology companies, worldwide.
Concurrently, the Company is seeking to monetize its existing
product pipeline, including compounds from pre-clinical through
Phase 3, currently focused on dermatology, sexual dysfunction and
cancer. For further information on NexMed and its subsidiaries,
visit the following websites: http://www.nexmed.com or
http://www.bio-quant.com.
Forward-Looking Statement Safe
Harbor
Statements under the Private Securities Litigation Reform Act:
with the exception of the historical information contained in this
release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may
individually or mutually impact the matters herein described for a
variety of reasons that are outside the control of the Company,
including but not limited to, its ability to obtain and/or enforce
patent coverage or partner in international markets.
Nexmed (MM) (NASDAQ:NEXM)
過去 株価チャート
から 5 2024 まで 6 2024
Nexmed (MM) (NASDAQ:NEXM)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Nexmed (MM) (ナスダック市場): 0 recent articles
その他のNexMed, Inc.ニュース記事